(Q46653217)

24 December 2017

title

Clinical response to morphine in cancer patients and genetic variation in candidate genes (English)

1 reference

24 December 2017

0 references

1 reference

1 reference

J R Ross

1

1 reference

24 December 2017

D Rutter

2

1 reference

24 December 2017

K Welsh

3

1 reference

24 December 2017

S P Joel

4

1 reference

24 December 2017

K Goller

5

1 reference

24 December 2017

A U Wells

6

1 reference

24 December 2017

R Du Bois

7

1 reference

24 December 2017

J Riley

8

1 reference

24 December 2017

publication date

1 January 2005

1 reference

24 December 2017

The Pharmacogenomics Journal

published in

1 reference

24 December 2017

volume

5

1 reference

24 December 2017

issue

5

1 reference

24 December 2017

page(s)

324-336

1 reference

24 December 2017

https://scigraph.springernature.com/pub.10.1038/sj.tpj.6500327

exact match

0 references

cites work

Strategies to manage the adverse effects of oral morphine: an evidence-based report.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

A retrospective study of the association between haematological and biochemical parameters and morphine intolerance in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Plasma concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide and their relationship with analgesia and side effects in patients with cancer-related pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Predicting response to lithium in mood disorders: role of genetic polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Opioids in pain management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Molecular pharmacology of the opioid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Opioid receptor signalling mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

PET imaging of opioid receptors in pain: progress and new directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Gender and age influences on human brain mu-opioid receptor binding measured by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

The human mu opioid receptor gene: 5' regulatory and intronic sequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Involvement of activator protein-1 in transcriptional regulation of the human mu-opioid receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Regulation of mu-opioid receptor gene transcription by interleukin-4 and influence of an allelic variation within a STAT6 transcription factor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

mu opiate receptor: cDNA cloning and expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

mu Opioid receptor: role for the amino terminus as a determinant of ligand binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

The role of the hydrophilic Asn230 residue of the mu-opioid receptor in the potency of various opioid agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

The use of intermittent subcutaneous injections of oxycodone for opioid rotation in patients with cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Mu opioid receptor gene variants: lack of association with alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Association analysis of polymorphisms in the μ opioid gene and heroin abuse in Chinese subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Sequence Variability and Candidate Gene Analysis in Two Cancer Patients with Complex Clinical Outcomes During Morphine Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Human mu opioid receptor gene polymorphisms and vulnerability to substance abuse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Opioid receptor and peptide gene polymorphisms: potential implications for addictions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

Topographic analysis of painful laser and sural nerve electrical evoked potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

The pharmacogenetics of codeine hypoalgesia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Peripheral mechanisms of opioid analgesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Detection and function of opioid receptors on cells from the immune system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Opioid analgesia: new information from gene knockout studies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Enhanced morphine analgesia in mice lacking beta-arrestin 2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

An improved method for the simultaneous determination of morphine and its principal glucuronide metabolites

1 reference

https://api.crossref.org/works/10.1038%2FSJ.TPJ.6500327

7 January 2021

Identifiers

DOI

10.1038/SJ.TPJ.6500327

1 reference

24 December 2017

1 reference

24 December 2017